Diabetes mellitus related bone metabolism and periodontal disease

International Journal of Oral Science

Volumn 7, Issue 2, 2015, Pages 63-72

  Wu, Ying Ying ^a,b   Xiao, E ^b,c   Graves, Dana T ^b  

^a SICHUAN UNIVERSITY   (China)

^b UNIVERSITY OF PENNSYLVANIA SCHOOL OF DENTAL MEDICINE   (United States)

^c PEKING UNIVERSITY SCHOOL AND HOSPITAL OF STOMATOLOGY   (China)

Author keywords

bone loss; diabetes mellitus; hyperglycemia; inflammation; osseous; osteoblast; osteoclast; periodontitis

Indexed keywords

BONE DISEASE; COMPLICATION; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; PERIODONTAL DISEASE;

BONE DISEASES; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; HUMANS; PERIODONTAL DISEASES;

EID: 84946842673     PISSN: 16742818     EISSN: 20493169     Source Type: Journal    
DOI: 10.1038/IJOS.2015.2     Document Type: Review

References (203)

1. Bell GI, Polonsky KS. Diabetes mellitus and genetically programmed defects in beta-cell function. Nature 2001; 414(6865): 788–791.
2. Kahn SE. Clinical review 135: the importance of beta-cell failure in the development and progression of type 2 diabetes. J Clin Endocrinol Metab 2001; 86(9): 4047– 4058.
3. Cavaghan MK, Ehrmann DA, Polonsky KS. Interactions between insulin resistance and insulin secretion in the development of glucose intolerance. J Clin Invest 2000; 106(3): 329–333.
4. Zimmet P, Alberti KG, Shaw J. Global and societal implications of the diabetes epidemic. Nature 2001; 414(6865): 782–787.
5. Kaul K, Tarr JM, Ahmad SI et al. Introduction to diabetes mellitus. Adv Exp Med Biol 2012; 771: 1–11.
6. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2009; 32 (Suppl 1): S62–S67.
7. SEARCH for Diabetes in Youth Study Group, Liese AD, D'Agostino RB Jr et al. The burden of diabetes mellitus among US youth: prevalence estimates from the SEARCH for Diabetes in Youth Study. Pediatrics 2006; 118(4): 1510–1518.
8. Soltesz G, Patterson CC, Dahlquist G et al. Worldwide childhood type 1 diabetes incidence—what can we learn from epidemiology? Pediatr Diabetes 2007; 8 (Suppl 6): 6–14.
9. Pinhas-Hamiel O, Zeitler P. The global spread of type 2 diabetes mellitus in children and adolescents. J Pediatr 2005; 146(5): 693–700.
10. Padgett LE, Broniowska KA, Hansen PA et al. The role of reactive oxygen species and proinflammatory cytokines in type 1 diabetes pathogenesis. Ann N Y Acad Sci 2013; 1281: 16–35.
11. Bluestone JA, Herold K, Eisenbarth G. Genetics, pathogenesis and clinical interventions in type 1 diabetes. Nature 2010; 464(7293): 1293–1300.
12. Anderson MS, Bluestone JA. The NOD mouse: a model of immune dysregulation. Annu Rev Immunol 2005; 23: 447–485.
13. van Belle TL, Coppieters KT, von Herrath MG. Type 1 diabetes: etiology, immunology, and therapeutic strategies. Physiol Rev 2011; 91(1): 79–118.
14. Nolan CJ, Damm P, Prentki M. Type 2 diabetes across generations: from patho-physiology to prevention and management. Lancet 2011; 378(9786): 169–181.
15. Prentki M, Nolan CJ. Islet beta cell failure in type 2 diabetes. J Clin Invest 2006; 116(7): 1802–1812.
16. Defronzo RA. Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes 2009; 58(4): 773–795.
17. Unger RH. Diabetic hyperglycemia: link to impaired glucose transport in pancreatic beta cells. Science 1991; 251(4998): 1200–1205.
18. Giacco F, Brownlee M. Oxidative stress and diabetic complications. Circ Res 2010; 107(9): 1058–1070.
19. Yerneni KK, Bai W, Khan BV et al. Hyperglycemia-induced activation of nuclear transcription factor kappaB in vascular smooth muscle cells. Diabetes 1999; 48(4): 855–864.
20. Kolm-Litty V, Sauer U, Nerlich A et al. High glucose-induced transforming growth factor beta1 production is mediated by the hexosamine pathway in porcine glomerular mesangial cells. J Clin Invest 1998; 101(1): 160–169.
21. Sayeski PP, Kudlow JE. Glucose metabolism to glucosamine is necessary for glucose stimulation of transforming growth factor-alpha gene transcription. J Biol Chem 1996; 271(25): 15237–15243.
22. Yan LJ. Pathogenesis of chronic hyperglycemia: from reductive stress to oxidative stress. J Diabetes Res 2014; 2014: 137919.
23. Degenhardt TP, Thorpe SR, Baynes JW. Chemical modification of proteins by methylglyoxal. Cell Mol Biol: Noisy-le-grand 1998; 44(7): 1139–1145.
24. Wells-Knecht KJ, Zyzak DV, Litchfield JE et al. Mechanism of autoxidative glycosylation: identification of glyoxal and arabinose as intermediates in the autoxidative modification of proteins by glucose. Biochemistry 1995; 34(11): 3702–3709.
25. Thornalley PJ. The glyoxalase system: new developments towards functional characterization of a metabolic pathway fundamental to biological life. Biochem J 1990; 269(1): 1–11.
26. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 2001; 414(6865): 813–820.
27. Reaven GM, Hollenbeck C, Jeng CY et al. Measurement of plasma glucose, free fatty acid, lactate, and insulin for 24 h in patients with NIDDM. Diabetes 1988; 37(8): 1020–1024.
28. Walker KZ, O'Dea K, Johnson L et al. Body fat distribution and non-insulin-dependent diabetes: comparison of a fiber-rich, high-carbohydrate, low-fat (23%) diet and a 35% fat diet high in monounsaturated fat. Am J Clin Nutr 1996; 63(2): 254–260.
29. Maedler K, Oberholzer J, Bucher P et al. Monounsaturated fatty acids prevent the deleterious effects of palmitate and high glucose on human pancreatic beta-cell turnover and function. Diabetes 2003; 52(3): 726–733.
30. Maedler K, Spinas GA, Dyntar D et al. Distinct effects of saturated and monoun-saturated fatty acids on beta-cell turnover and function. Diabetes 2001; 50(1): 69– 76.
31. Unger RH. Lipotoxicity in the pathogenesis of obesity-dependent NIDDM. Genetic and clinical implications. Diabetes 1995; 44(8): 863–870.
32. Cusi K. The role of adipose tissue and lipotoxicity in the pathogenesis of type 2 diabetes. Curr Diab Rep 2010; 10(4): 306–315.
33. Evans JL, Goldfine ID, Maddux BA et al. Oxidative stress and stress-activated signaling pathways: a unifying hypothesis of type 2 diabetes. Endocr Rev 2002; 23(5): 599– 622.
34. Evans JL, Goldfine ID, Maddux BA et al. Are oxidative stress-activated signaling pathways mediators of insulin resistance and beta-cell dysfunction? Diabetes 2003; 52(1): 1–8.
35. Pitocco D, Zaccardi F, Di Stasio E et al. Oxidative stress, nitric oxide, and diabetes. Rev Diabet Stud 2010; 7(1): 15–25.
36. Niedowicz DM, Daleke DL. The role of oxidative stress in diabetic complications. Cell Biochem Biophys 2005; 43(2): 289–330.
37. Valle A, Giamporcaro GM, Scavini M et al. Reduction of circulating neutrophils precedes and accompanies type 1 diabetes. Diabetes 2013; 62(6): 2072–2077.
38. Harsunen MH, Puff R, D'Orlando O et al. Reduced blood leukocyte and neutrophil numbers in the pathogenesis of type 1 diabetes. Horm Metab Res 2013; 45(6): 467– 470.
39. Battaglia M. Neutrophils and type 1 autoimmune diabetes. Curr Opin Hematol 2014; 21(1): 8–15.
40. Ding Y, Kantarci A, Hasturk H et al. Activation of RAGE induces elevated O2-generation by mononuclear phagocytes in diabetes. J Leukoc Biol 2007; 81(2): 520–527.
41. Bradshaw EM, Raddassi K, Elyaman W et al. Monocytes from patients with type 1 diabetes spontaneously secrete proinflammatory cytokines inducing Th17 cells. J Immunol 2009; 183(7): 4432–4439.
42. Espinoza-Jiménez A, Peón AN, Terrazas LI. Alternatively activated macrophages in types 1 and 2 diabetes. Mediators Inflamm 2012; 2012: 815953.
43. Lontchi-Yimagou E, Sobngwi E, Matsha TE et al. Diabetes mellitus and inflammation. Curr Diab Rep 2013; 13(3): 435–444.
44. Cruz NG, Sousa LP, Sousa MO et al. The linkage between inflammation and Type 2 diabetes mellitus. Diabetes Res Clin Pract 2013; 99(2): 85–92.
45. Johnson DR, O'Connor JC, Satpathy A et al. Cytokines in type 2 diabetes. Vitam Horm 2006; 74: 405–441.
46. Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 1993; 259 (5091): 87–91.
47. Nikolajczyk BS, Jagannathan-Bogdan M, Shin H et al. State of the union between metabolism and the immune system in type 2 diabetes. Genes Immun 2011; 12(4): 239–250.
48. Graves DT, Kayal RA. Diabetic complications and dysregulated innate immunity. Front Biosci 2008; 13: 1227–1239.
49. Pham MN, Kolb H, Battelino T et al. Fasting and meal-stimulated residual beta cell function is positively associated with serum concentrations of proinflammatory cytokines and negatively associated with anti-inflammatory and regulatory cytokines in patients with longer term type 1 diabetes. Diabetologia 2013; 56(6): 1356–1363.
50. Herder C, Carstensen M, Ouwens DM. Anti-inflammatory cytokines and risk of type 2 diabetes. Diabetes Obes Metab 2013; 15 (Suppl 3): 39–50.
51. Akash MS, Rehman K, Chen S. IL-1Ra and its delivery strategies: inserting the association in perspective. Pharm Res 2013; 30(11): 2951–2966.
52. Ardestani A, Sauter NS, Paroni F et al. Neutralizing interleukin-1beta (IL-1beta) induces beta-cell survival by maintaining PDX1 protein nuclear localization. J Biol Chem 2011; 286(19): 17144–17155.
53. Li S, Shin HJ, Ding EL et al. Adiponectin levels and risk of type 2 diabetes: a systematic review and meta-analysis. JAMA 2009; 302(2): 179–188.
54. Tandon N, Ali MK, Narayan KM. Pharmacologic prevention of microvascular and macrovascular complications in diabetes mellitus: implications of the results of recent clinical trials in type 2 diabetes. Am J Cardiovasc Drugs 2012; 12(1): 7–22.
55. Mattila TK, de Boer A. Influence of intensive versus conventional glucose control on microvascular and macrovascular complications in type 1 and 2 diabetes mellitus. Drugs 2010; 70(17): 2229–2245.
56. Gerstein HC, Pogue J, Mann JF et al. The relationship between dysglycaemia and cardiovascular and renal risk in diabetic and non-diabetic participants in the HOPE study: a prospective epidemiological analysis. Diabetologia 2005; 48(9): 1749– 1755.
57. Laakso M. Hyperglycemia and cardiovascular disease in type 2 diabetes. Diabetes 1999; 48(5): 937–942.
58. Roy S, Sato T, Paryani G et al. Downregulation of fibronectin overexpression reduces basement membrane thickening and vascular lesions in retinas of galactose-fed rats. Diabetes 2003; 52(5): 1229–1234.
59. Chilelli NC, Burlina S, Lapolla A. AGEs, rather than hyperglycemia, are responsible for microvascular complications in diabetes: a ‘‘glycoxidation-centric’’ point of view. Nutr Metab Cardiovasc Dis 2013; 23(10): 913–919.
60. Behl Y, Krothapalli P, Desta T et al. Diabetes-enhanced tumor necrosis factor-alpha production promotes apoptosis and the loss of retinal microvascular cells in type 1 and type 2 models of diabetic retinopathy. Am J Pathol 2008; 172(5): 1411–1418.
61. Behl Y, Krothapalli P, Desta T et al. FOXO1 plays an important role in enhanced microvascular cell apoptosis and microvascular cell loss in type 1 and type 2 diabetic rats. Diabetes 2009; 58(4): 917–925.
62. Davey GC, Patil SB, O'Loughlin A et al. Mesenchymal stem cell-based treatment for microvascular and secondary complications of diabetes mellitus. Front Endocrinol: Lausanne 2014; 5: 86.
63. Ferris FL 3rd, Davis MD, Aiello LM. Treatment of diabetic retinopathy. N Engl J Med 1999; 341(9): 667–678.
64. Han JW, Sin MY, Yoon YS. Cell therapy for diabetic neuropathy using adult stem or progenitor cells. Diabetes Metab J 2013; 37(2): 91–105.
65. Gooch C, Podwall D. The diabetic neuropathies. Neurologist 2004; 10(6): 311–322.
66. Duran-Salgado MB, Rubio-Guerra AF. Diabetic nephropathy and inflammation. World J Diabetes 2014; 5(3): 393–398.
67. Yamagishi S, Fukami K, Ueda S et al. Molecular mechanisms of diabetic nephropathy and its therapeutic intervention. Curr Drug Targets 2007; 8(8): 952–959.
68. Ziyadeh FN, Wolf G. Pathogenesis of the podocytopathy and proteinuria in diabetic glomerulopathy. Curr Diabetes Rev 2008; 4(1): 39–45.
69. Valkusz Z. [Diabetes and osteoporosis.] Orv Hetil 2011; 152(29): 1161–1166. Hungarian.
70. Vestergaard P, Rejnmark L, Mosekilde L. Relative fracture risk in patients with diabetes mellitus, and the impact of insulin and oral antidiabetic medication on relative fracture risk. Diabetologia 2005; 48(7): 1292–1299.
71. Vestergaard P. Discrepancies in bone mineral density and fracture risk in patients with type 1 and type 2 diabetes—a meta-analysis. Osteoporos Int 2007; 18(4): 427–444.
72. Holmberg AH, Johnell O, Nilsson PM et al. Risk factors for fragility fracture in middle age. A prospective population-based study of 33 000 men and women. Osteoporos Int 2006; 17(7): 1065–1077.
73. Bonds DE, Larson JC, Schwartz AV et al. Risk of fracture in women with type 2 diabetes: the Women’s Health Initiative Observational Study. J Clin Endocrinol Metab 2006; 91(9): 3404–3410.
74. Heap J, Murray MA, Miller SC et al. Alterations in bone characteristics associated with glycemic control in adolescents with type 1 diabetes mellitus. J Pediatr 2004; 144(1): 56–62.
75. Okazaki R. [Management of osteoporosis in diabetes mellitus.] Nippon Rinsho 2009; 67(5): 1003–1010. Japanese.
76. Schwartz AV, Hillier TA, Sellmeyer DE et al. Older women with diabetes have a higher risk of falls: a prospective study. Diabetes Care 2002; 25(10): 1749–1754.
77. Saito M, Fujii K, Mori Y et al. Role of collagen enzymatic and glycation induced cross-links as a determinant of bone quality in spontaneously diabetic WBN/Kob rats. Osteoporos Int 2006; 17(10): 1514–1523.
78. Sau, K.,P., Chaki, T.,K., Khastgir, D., “Conductive rubber composites from different blends of ethylene-propylene-diene rubber and nitrile rubber”, Journal of Materials Science 32, 1997, pp 5717-5724.
79. Duarte VM, Ramos AM, Rezende LA et al. Osteopenia: a bone disorder associated with diabetes mellitus. J Bone Miner Metab 2005; 23(1): 58–68.
80. Williams GA, Callon KE, Watson M et al. Skeletal phenotype of the leptin receptor-deficient db/db mouse. J Bone Miner Res 2011; 26(8): 1698–1709.
81. Turner RT, Kalra SP, Wong CP et al. Peripheral leptin regulates bone formation. J Bone Miner Res 2013; 28(1): 22–34.
82. Suzuki K, Kurose T, Takizawa M et al. Osteoclastic function is accelerated in male patients with type 2 diabetes mellitus: the preventive role of osteoclastogenesis inhibitory factor/osteoprotegerin (OCIF/OPG) on the decrease of bone mineral density. Diabetes Res Clin Pract 2005; 68(2): 117–125.
83. Gerdhem P, Isaksson A, Akesson K et al. Increased bone density and decreased bone turnover, but no evident alteration of fracture susceptibility in elderly women with diabetes mellitus. Osteoporos Int 2005; 16(12): 1506–1512.
84. Norris R, Parker M. Diabetes mellitus and hip fracture: a study of 5966 cases. Injury 2011; 42(11): 1313–1316.
85. Perlman MH, Thordarson DB. Ankle fusion in a high risk population: an assessment of nonunion risk factors. Foot Ankle Int 1999; 20(8): 491–496.
86. Brown ML, Yukata K, Farnsworth CW et al. Delayed fracture healing and increased callus adiposity in a C57BL/6J murine model of obesity-associated type 2 diabetes mellitus. PLoS One 2014; 9(6): e99656.
87. Kayal RA, Tsatsas D, Bauer MA et al. Diminished bone formation during diabetic fracture healing is related to the premature resorption of cartilage associated with increased osteoclast activity. J Bone Miner Res 2007; 22(4): 560–568.
88. Lozano D, de Castro LF, Dapía S et al. Role of parathyroid hormone-related protein in the decreased osteoblast function in diabetes-related osteopenia. Endocrinology 2009; 150(5): 2027–2035.
89. Alikhani M, Alikhani Z, Boyd C et al. Advanced glycation end products stimulate osteoblast apoptosis via the MAP kinase and cytosolic apoptotic pathways. Bone 2007; 40(2): 345–353.
90. Lu H, Kraut D, Gerstenfeld LC et al. Diabetes interferes with the bone formation by affecting the expression of transcription factors that regulate osteoblast differen-tiation. Endocrinology 2003; 144(1): 346–352.
91. Hamann C, Goettsch C, Mettelsiefen J et al. Delayed bone regeneration and low bone mass in a rat model of insulin-resistant type 2 diabetes mellitus is due to impaired osteoblast function. Am J Physiol Endocrinol Metab 2011; 301(6): E1220–E1228.
92. Weinberg E, Maymon T, Moses O et al. Streptozotocin-induced diabetes in rats diminishes the size of the osteoprogenitor pool in bone marrow. Diabetes Res Clin Pract 2014; 103(1): 35–41.
93. Santana RB, Xu L, Chase HB et al. A role for advanced glycation end products in diminished bone healing in type 1 diabetes. Diabetes 2003; 52(6): 1502–1510.
94. Schett G. Effects of inflammatory and anti-inflammatory cytokines on the bone. Eur J Clin Invest 2011; 41(12): 1361–1366.
95. Alblowi J, Kayal RA, Siqueira M et al. High levels of tumor necrosis factor-alpha contribute to accelerated loss of cartilage in diabetic fracture healing. Am J Pathol 2009; 175(4): 1574–1585.
96. Liu R, Bal HS, Desta T et al. Tumor necrosis factor-alpha mediates diabetes-enhanced apoptosis of matrix-producing cells and impairs diabetic healing. Am J Pathol 2006; 168(3): 757–764.
97. Al-Mashat HA, Kandru S, Liu R et al. Diabetes enhances mRNA levels of proapoptotic genes and caspase activity, which contribute to impaired healing. Diabetes 2006; 55(2): 487–495.
98. Kayal RA, Siqueira M, Alblowi J et al. TNF-alpha mediates diabetes-enhanced chondrocyte apoptosis during fracture healing and stimulates chondrocyte apoptosis through FOXO1. J Bone Miner Res 2010; 25(7): 1604–1615.
99. Gilbert LC, Rubin J, Nanes MS. The p55 TNF receptor mediates TNF inhibition of osteoblast differentiation independently of apoptosis. Am J Physiol Endocrinol Metab 2005; 288(5): E1011–E1018.
100. Chang J, Liu F, Lee M et al. NF-kB inhibits osteogenic differentiation of mesenchymal stem cells by promoting β-catenin degradation. Proc Natl Acad Sci U S A 2013; 110(23): 9469–9474.
101. Lu X, Beck GR Jr, Gilbert LC et al. Identification of the homeobox protein Prx1 (MHox, Prrx-1) as a regulator of osterix expression and mediator of tumor necrosis factor α action in osteoblast differentiation. J Bone Miner Res 2011; 26(1): 209–219.
102. Stolzing A, Sellers D, Llewelyn O et al. Diabetes induced changes in rat mesenchymal stem cells. Cells Tissues Organs: Print 2010; 191(6): 453–465.
103. Kume S, Kato S, Yamagishi S et al. Advanced glycation end-products attenuate human mesenchymal stem cells and prevent cognate differentiation into adipose tissue, cartilage, and bone. J Bone Miner Res 2005; 20(9): 1647–1658.
104. Notsu M, Yamaguchi T, Okazaki K et al. Advanced glycation end product 3 (AGE3) suppresses the mineralization of mouse stromal ST2 cells and human mesenchymal stem cells by increasing TGF-β expression and secretion. Endocrinology 2014; 155(7): 2402–2410.
105. Shin L, Peterson DA. Impaired therapeutic capacity of autologous stem cells in a model of type 2 diabetes. Stem Cells Transl Med 2012; 1(2): 125–135.
106. Takizawa M, Suzuki K, Matsubayashi T et al. Increased bone resorption may play a crucial role in the occurrence of osteopenia in patients with type 2 diabetes: possible involvement of accelerated polyol pathway in its pathogenesis. Diabetes Res Clin Pract 2008; 82(1): 119–126.
107. Reyes-García R, Rozas-Moreno P, López-Gallardo G et al. Serum levels of bone resorption markers are decreased in patients with type 2 diabetes. Acta Diabetol 2013; 50(1): 47–52.
108. Suzuki K, Ishida H, Takeshita N et al. Circulating levels of tartrate-resistant acid phosphatase in rat models of non-insulin-dependent diabetes mellitus. J Diabetes Complicat 1998; 12(3): 176–180.
109. Alblowi J, Tian C, Siqueira MF et al. Chemokine expression is upregulated in chondrocytes in diabetic fracture healing. Bone 2013; 53(1): 294–300.
110. Hie M, Shimono M, Fujii K et al. Increased cathepsin K and tartrate-resistant acid phosphatase expression in bone of streptozotocin-induced diabetic rats. Bone 2007; 41(6): 1045–1050.
111. Liu R, Bal HS, Desta T et al. Diabetes enhances periodontal bone loss through enhanced resorption and diminished bone formation. JDentRes2006; 85(6): 510–514.
112. Jeffcoate WJ, Game F, Cavanagh PR. The role of proinflammatory cytokines in the cause of neuropathic osteoarthropathy (acute Charcot foot) in diabetes. Lancet 2005; 366(9502): 2058–2061.
113. Ha H, Kwak HB, Lee SW et al. Reactive oxygen species mediate RANK signaling in osteoclasts. Exp Cell Res 2004; 301(2): 119–127.
114. Drosatos-Tampakaki Z, Drosatos K, Siegelin Y et al. Palmitic acid and DGAT1 deficiency enhance osteoclastogenesis, while oleic acid-induced triglyceride formation prevents it. J Bone Miner Res 2014; 29(5): 1183–1195.
115. Catalfamo DL, Britten TM, Storch DL et al. Hyperglycemia induced and intrinsic alterations in type 2 diabetes-derived osteoclast function. Oral Dis 2013; 19(3): 303–312.
116. Miyata T, Kawai R, Taketomi S et al. Possible involvement of advanced glycation end-products in bone resorption. Nephrol Dial Transplant 1996; 11 (Suppl 5): 54–57.
117. Ding KH, Wang ZZ, Hamrick MW et al. Disordered osteoclast formation in RAGE-deficient mouse establishes an essential role for RAGE in diabetes related bone loss. Biochem Biophys Res Commun 2006; 340(4): 1091–1097.
118. Graves DT, Li J, Cochran DL. Inflammation and uncoupling as mechanisms of periodontal bone loss. J Dent Res 2011; 90(2): 143–153.
119. Borrell LN, Papapanou PN. Analytical epidemiology of periodontitis. J Clin Periodontol 2005; 32 (Suppl 6): 132–158.
120. Eke PI, Dye BA, Wei L et al. Prevalence of periodontitis in adults in the United States: 2009 and 2010. J Dent Res 2012; 91(10): 914–920.
121. Dye BA. Global periodontal disease epidemiology. Periodontol 2000 2012; 58(1): 10–25.
122. Bascones-Martínez A, González-Febles J, Sanz-Esporrín J. Diabetes and periodontal disease. Review of the literature. Am J Dent 2014; 27(2): 63–67.
123. Pihlstrom BL, Michalowicz BS, Johnson NW. Periodontal diseases. Lancet 2005; 366(9499): 1809–1820.
124. Tanaka K, Miyake Y, Hanioka T et al. Relationship between IL1 gene polymorphisms and periodontal disease in Japanese women. DNA Cell Biol 2014; 33(4): 227–233.
125. Tsaousoglou P, Nietzsche S, Cachovan G et al. Antibacterial activity of moxifloxacin on bacteria associated with periodontitis within a biofilm. J Med Microbiol 2014; 63(Pt 2): 284–292.
126. Jünemann S, Prior K, Szczepanowski R et al. Bacterial community shift in treated periodontitis patients revealed by ion torrent 16S rRNA gene amplicon sequencing. PLoS One 2012; 7(8): e41606.
127. Socransky SS, Haffajee AD, Cugini MA et al. Microbial complexes in subgingival plaque. J Clin Periodontol 1998; 25(2): 134–144.
128. Griffen AL, Beall CJ, Campbell JH et al. Distinct and complex bacterial profiles in human periodontitis and health revealed by 16S pyrosequencing. ISME J 2012; 6(6): 1176–1185.
129. Hajishengallis G, Liang S, Payne MA et al. Low-abundance biofilm species orchestrates inflammatory periodontal disease through the commensal microbiota and complement. Cell Host Microbe 2011; 10(5): 497–506.
130. Jiao Y, Hasegawa M, Inohara N. Emerging roles of immunostimulatory oral bacteria in periodontitis development. Trends Microbiol 2014; 22(3): 157–163.
131. Kumar PS, Griffen AL, Moeschberger ML et al. Identification of candidate periodontal pathogens and beneficial species by quantitative 16S clonal analysis. J Clin Microbiol 2005; 43(8): 3944–3955.
132. Kumar PS, Leys EJ, Bryk JM et al. Changes in periodontal health status are associated with bacterial community shifts as assessed by quantitative 16S cloning and sequencing. J Clin Microbiol 2006; 44(10): 3665–3673.
133. Haffajee AD, Bogren A, Hasturk H et al. Subgingival microbiota of chronic periodontitis subjects from different geographic locations. J Clin Periodontol 2004; 31(11): 996–1002.
134. Graves DT, Oates T, Garlet GP. Review of osteoimmunology and the host response in endodontic and periodontal lesions. J Oral Microbiol 2011; 3.
135. Boström L, Bergström J, Dahlén G et al. Smoking and subgingival microflora in periodontal disease. J Clin Periodontol 2001; 28(3): 212–219.
136. Williams RC, Jeffcoat MK, Kaplan ML et al. Flurbiprofen: a potent inhibitor of alveolar bone resorption in beagles. Science 1985; 227(4687): 640–642.
137. Assuma R, Oates T, Cochran D et al. IL-1 and TNF antagonists inhibit the inflammatory response and bone loss in experimental periodontitis. J Immunol 1998; 160(1): 403– 409.
138. Delima AJ, Karatzas S, Amar S et al. Inflammation and tissue loss caused by periodontal pathogens is reduced by interleukin-1 antagonists. J Infect Dis 2002; 186(4): 511–516.
139. Hajishengallis G. Aging and its impact on innate immunity and inflammation: implications for periodontitis. J Oral Biosci 2014; 56(1): 30–37.
140. Loos BG, Papantonopoulos G. Molecular biotypes for periodontal diseases? J Dent Res 2013; 92(12): 1056–1057.
141. Albert DA, Ward A, Allweiss P et al. Diabetes and oral disease: implications for health professionals. Ann N Y Acad Sci 2012; 1255: 1–15.
142. Bullon P, Newman HN, Battino M. Obesity, diabetes mellitus, atherosclerosis and chronic periodontitis: a shared pathology via oxidative stress and mitochondrial dysfunction? Periodontol 2000 2014; 64(1): 139–153.
143. Tsai C, Hayes C, Taylor GW. Glycemic control of type 2 diabetes and severe periodontal disease in the US adult population. Community Dent Oral Epidemiol 2002; 30(3): 182–192.
144. Preshaw PM, Bissett SM. Periodontitis: oral complication of diabetes. Endocrinol Metab Clin North Am 2013; 42(4): 849–867.
145. Löe H. Periodontal disease. The sixth complication of diabetes mellitus. Diabetes Care 1993; 16(1): 329–334.
146. Pop awska-Kita A, Siewko K, Szpak P et al. Association between type 1 diabetes and periodontal health. Adv Med Sci 2014; 59(1): 126–131.
147. Xavier AC, Silva IN, Costa Fde O et al. [Periodontal status in children and adolescents with type 1 diabetes mellitus.] Arq Bras Endocrinol Metabol 2009; 53(3): 348–354. Portuguese.
148. Leite RS, Marlow NM, Fernandes JK. Oral health and type 2 diabetes. Am J Med Sci 2013; 345(4): 271–273.
149. Fernandes JK, Wiegand RE, Salinas CF et al. Periodontal disease status in gullah african americans with type 2 diabetes living in South Carolina. J Periodontol 2009; 80(7): 1062–1068.
150. Al-Khabbaz AK. Type 2 diabetes mellitus and periodontal disease severity. Oral Health Prev Dent 2014; 12(1): 77–82.
151. Apoorva SM, Sridhar N, Suchetha A. Prevalence and severity of periodontal disease in type 2 diabetes mellitus (non-insulin-dependent diabetes mellitus) patients in Bangalore city: an epidemiological study. J Indian Soc Periodontol 2013; 17(1): 25–29.
152. Ryan ME, Carnu O, Kamer A. The influence of diabetes on the periodontal tissues. J Am Dent Assoc 2003; 134 (Spec No): 34S–40S.
153. Orbak R, Simsek S, Orbak Z et al. The influence of type-1 diabetes mellitus on dentition and oral health in children and adolescents. Yonsei Med J 2008; 49(3): 357–365.
154. Costa CC, Resende GB, Souza JM et al. [Study of the oral manifestations in diabetic children and their correlation variables.] Arq Bras Endocrinol Metabol 2004; 48(3): 374–378. Portuguese.
155. Albandar JM, Tinoco EM. Global epidemiology of periodontal diseases in children and young persons. Periodontol 2000 2002; 29: 153–176.
156. Katagiri S, Nagasawa T, Kobayashi H et al. Improvement of glycemic control after periodontal treatment by resolving gingival inflammation in type 2 diabetic patients with periodontal disease. J Diabetes Investig 2012; 3(4): 402–409.
157. Kang J, de Brito Bezerra B, Pacios S et al. Aggregatibacter actinomycetemcomitans infection enhances apoptosis in vivo through a caspase-3-dependent mechanism in experimental periodontitis. Infect Immun 2012; 80(6): 2247–2256.
158. Graves DT, Liu R, Oates TW. Diabetes-enhanced inflammation and apoptosis: impact on periodontal pathosis. Periodontol 2000 2007; 45: 128–137.
159. Ponugoti B, Dong G, Graves DT. Role of forkhead transcription factors in diabetes-induced oxidative stress. Exp Diabetes Res 2012; 2012: 939751.
160. Andriankaja OM, Galicia J, Dong G et al. Gene expression dynamics during diabetic periodontitis. J Dent Res 2012; 91(12): 1160–1165.
161. Pacios S, Andriankaja O, Kang J et al. Bacterial infection increases periodontal bone loss in diabetic rats through enhanced apoptosis. Am J Pathol 2013; 183(6): 1928– 1935.
162. Mealey BL, Rose LF. Diabetes mellitus and inflammatory periodontal diseases. Curr Opin Endocrinol Diabetes Obes 2008; 15(2): 135–141.
163. Lalla E, Cheng B, Lal S et al. Diabetes mellitus promotes periodontal destruction in children. J Clin Periodontol 2007; 34(4): 294–298.
164. Deshpande K, Jain A, Sharma R et al. Diabetes and periodontitis. JIndianSoc Periodontol 2010; 14(4): 207–212.
165. Tervonen T, Karjalainen K, Knuuttila M et al. Alveolar bone loss in type 1 diabetic subjects. J Clin Periodontol 2000; 27(8): 567–571.
166. Kim JH, Lee DE, Gunawardhana KS et al. Effect of the interaction between periodontitis and type 1 diabetes mellitus on alveolar bone, mandibular condyle and tibia. Acta Odontol Scand 2014; 72(4): 265–273.
167. Kim JH, Lee DE, Choi SH et al. Diabetic characteristics and alveolar bone loss in streptozotocin-and streptozotocin-nicotinamide-treated rats with periodontitis. J Periodont Res 2014; 49(6): 792–800.
168. Taylor GW, Burt BA, Becker MP et al. Non-insulin dependent diabetes mellitus and alveolar bone loss progression over 2 years. J Periodontol 1998; 69(1): 76–83.
169. Taylor GW, Burt BA, Becker MP et al. Glycemic control and alveolar bone loss progression in type 2 diabetes. Ann Periodontol 1998; 3(1): 30–39.
170. Pacios S, Kang J, Galicia J et al. Diabetes aggravates periodontitis by limiting repair through enhanced inflammation. FASEB J 2012; 26(4): 1423–1430.
171. Silva JA, Lopes Ferrucci D, Peroni LA et al. Periodontal disease-associated compensatory expression of osteoprotegerin is lost in type 1 diabetes mellitus and correlates with alveolar bone destruction by regulating osteoclastogenesis. Cells Tissues Organs: Print 2012; 196(2): 137–150.
172. Graves DT, Naguib G, Lu H et al. Inflammation is more persistent in type 1 diabetic mice. J Dent Res 2005; 84(4): 324–328.
173. Naguib G, Al-Mashat H, Desta T et al. Diabetes prolongs the inflammatory response to a bacterial stimulus through cytokine dysregulation. J Invest Dermatol 2004; 123(1): 87–92.
174. Hasturk H, Kantarci A, Goguet-Surmenian E et al. Resolvin E1 regulates inflammation at the cellular and tissue level and restores tissue homeostasis in vivo. J Immunol 2007; 179(10): 7021–7029.
175. Andriankaja OM, Galicia J, Dong G et al. Gene expression dynamics during diabetic periodontitis. J Dent Res 2012; 91(12): 1160–1165.
176. Southerland JH, Taylor GT, Offenbacher S. Diabetes and periodontal infection: making the connection. Clin Diab 2005; 23(4): 171–178.
177. Silva JA, Ferrucci DL, Peroni LA et al. Sequential IL-23 and IL-17 and increased Mmp8 and Mmp14 expression characterize the progression of an experimental model of periodontal disease in type 1 diabetes. J Cell Physiol 2012; 227(6): 2441–2450.
178. Duarte PM, de Oliveira MC, Tambeli CH et al. Overexpression of interleukin-1beta and interleukin-6 may play an important role in periodontal breakdown in type 2 diabetic patients. J Periodont Res 2007; 42(4): 377–381.
179. Bastos AS, Graves DT, Loureiro AP et al. Lipid peroxidation is associated with the severity of periodontal disease and local inflammatory markers in patients with type 2 diabetes. J Clin Endocrinol Metab 2012; 97(8): E1353–E1362.
180. Lappin DF, Eapen B, Robertson D et al. Markers of bone destruction and formation and periodontitis in type 1 diabetes mellitus. J Clin Periodontol 2009; 36(8): 634–641.
181. + T-cells trigger RANKL-mediated enhanced alveolar bone loss in diabetic NOD mice. Diabetes 2005; 54(5): 1477–1486.
182. Santos VR, Lima JA, Gonçalves TE et al. Receptor activator of nuclear factor-kappa B ligand/osteoprotegerin ratio in sites of chronic periodontitis of subjects with poorly and well-controlled type 2 diabetes. J Periodontol 2010; 81(10): 1455–1465.
183. Brownlee M, Cerami A, Vlassara H. Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. N Engl J Med 1988; 318(20): 1315–1321.
184. Zizzi A, Tirabassi G, Aspriello SD et al. Gingival advanced glycation end-products in diabetes mellitus-associated chronic periodontitis: an immunohistochemical study. J Periodont Res 2013; 48(3): 293–301.
185. Lamster IB. Diabetes mellitus and oral health: an interprofessional approach. Ames: John Wiley & Sons, 2014: 130.
186. Mealey BL, Oates TW, American Academy of Periodontology. Diabetes mellitus and periodontal diseases. J Periodontol 2006; 77(8): 1289–1303.
187. Sies H. Oxidative stress: oxidants and antioxidants. Exp Physiol 1997; 82(2): 291– 295.
188. Steinbeck MJ, Appel WH Jr, Verhoeven AJ et al. NADPH-oxidase expression and in situ production of superoxide by osteoclasts actively resorbing bone. J Cell Biol 1994; 126(3): 765–772.
189. Thomas B, Ramesh A, Suresh S et al. A comparative evaluation of antioxidant enzymes and selenium in the serum of periodontitis patients with diabetes mellitus type 2. Contemp Clin Dent 2013; 4(2): 176–180.
190. Garrett IR, Boyce BF, Oreffo RO et al. Oxygen-derived free radicals stimulate osteoclastic bone resorption in rodent bone in vitro and in vivo. J Clin Invest 1990; 85(3): 632–639.
191. Collin HL, Sorsa T, Meurman JH et al. Salivary matrix metalloproteinase (MMP-8) levels and gelatinase (MMP-9) activities in patients with type 2 diabetes mellitus. J Periodont Res 2000; 35(5): 259–265.
192. Fu YW, He HB, Ou JG. [Osteoblast apoptosis in experimental diabetic periodontitis in rats.] Hua Xi Kou Qiang Yi Xue Za Zhi 2009; 27(3): 252–255, 259. Chinese.
193. Behl Y, Siqueira M, Ortiz J et al. Activation of the acquired immune response reduces coupled bone formation in response to a periodontal pathogen. J Immunol 2008; 181(12): 8711–8718.
194. Isaka J, Ohazama A, Kobayashi M et al. Participation of periodontal ligament cells with regeneration of alveolar bone. J Periodontol 2001; 72(3): 314–323.
195. He H, Liu R, Desta T et al. Diabetes causes decreased osteoclastogenesis, reduced bone formation, and enhanced apoptosis of osteoblastic cells in bacteria stimulated bone loss. Endocrinology 2004; 145(1): 447–452.
196. Naguib G, Al-Mashat H, Desta T et al. Diabetes prolongs the inflammatory response to a bacterial stimulus through cytokine dysregulation. J Invest Dermatol 2004; 123(1): 87–92.
197. Lalla E, Lamster IB, Schmidt AM. Enhanced interaction of advanced glycation end products with their cellular receptor RAGE: implications for the pathogenesis of accelerated periodontal disease in diabetes. Ann Periodontol 1998; 3(1): 13–19.
198. Taylor JJ, Preshaw PM, Lalla E. A review of the evidence for pathogenic mechanisms that may link periodontitis and diabetes. J Periodontol 2013; 84(4 Suppl): S113– S134.
199. Chapple IL, Genco R, working group 2 of the joint EFP/AAP workshop. Diabetes and periodontal diseases: consensus report of the Joint EFP/AAP Workshop on Periodontitis and Systemic Diseases. J Periodontol 2013; 84(4 Suppl): S106–S112.
200. Hein G, Weiss C, Lehmann G et al. Advanced glycation end product modification of bone proteins and bone remodelling: hypothesis and preliminary immunohistochemical findings. Ann Rheum Dis 2006; 65(1): 101–104.
201. Fu YW, He HB. Apoptosis of periodontium cells in streptozototocin-and ligature-induced experimental diabetic periodontitis in rats. Acta Odontol Scand 2013; 71(5): 1206–1215.
202. Ohnishi T, Bandow K, Kakimoto K et al. Oxidative stress causes alveolar bone loss in metabolic syndrome model mice with type 2 diabetes. J Periodont Res 2009; 44(1): 43–51.
203. Wang GW, Klein JB, Kang YJ. Metallothionein inhibits doxorubicin-induced mitochondrial cytochrome c release and caspase-3 activation in cardiomyocytes. J Pharmacol Exp Ther 2001; 298(2): 461–468.